SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
Indigo Pharmaceuticals, Inc. Signs License Agreement for INDI-702, a Drug for the Treatment of Arteriosclerosis Obliterans, With Nissan Chemical Industries, Ltd. and Taisho Pharmaceutical